| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Anlotinib plus radiotherapy or chemoradiotherapy in locally advanced or advanced esophageal squamous cell carcinoma: A multicohort, real-world study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Guo-Jie Feng, Cheng-Rui Fu, Fan Wang, Jian-Cheng Li, Yue Jiang, Xin-Yi Wang, Bai-Hua Yang, Wen-Cai Xu, Yao-Wen Zhang, Xin-Yu Cheng, Xiao-Lin Ge, Xiao-Jie Xia, He-Ming Xi, Xue-Song Zhao, Hong-Bing Ma, Xi-Xi Zhao, Xin Wang and Bao-Sheng Li |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xin Wang, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Panjiayuannanli, Chaoyang District, Beijing 100000, China. beryl_wx2000@163.com |
| Key Words |
Anlotinib; Radiotherapy; Chemoradiotherapy; Locally advanced or advanced; Esophageal cancer; Esophageal squamous cell carcinoma |
| Core Tip |
Despite established standard treatments for locally advanced or advanced esophageal squamous cell carcinoma, patient survival and disease control remain suboptimal. This multicenter, real-world, retrospective study observed that anlotinib combined with radiotherapy or chemoradiotherapy (CRT) was associated with encouraging overall survival and disease control, with manageable toxicity. Propensity score matching analysis was further conducted to explore potential differences in efficacy between this regimen and standard CRT. These hypothesis-generating findings provide real-world evidence for anlotinib plus radiotherapy or CRT in this population and warrant further prospective investigation. |
| Publish Date |
2026-11-20 02:04 |
| Citation |
Feng GJ, Fu CR, Wang F, Li JC, Jiang Y, Wang XY, Yang BH, Xu WC, Zhang YW, Cheng XY, Ge XL, Xia XJ, Xi HM, Zhao XS, Ma HB, Zhao XX, Wang X, Li BS. Anlotinib plus radiotherapy or chemoradiotherapy in locally advanced or advanced esophageal squamous cell carcinoma: A multicohort, real-world study. World J Gastroenterol 2027; 33(3): 123331
|
| URL |
https://www.wjgnet.com/1007-9327/full/v33/i3/123331.htm |
| DOI |
https://doi.org/10.3748/wjg.123331 |